Država: Irska
Jezik: engleski
Izvor: HPRA (Health Products Regulatory Authority)
HISTRELIN ACETATE
Orion Corporation
HISTRELIN ACETATE
50 Milligram
Implant
Product subject to prescription which may not be renewed (A)
Authorised
0000-00-00
PACKAGE LEAFLET: INFORMATION FOR THE USER Vantas 50 mg implant histrelin acetate READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours. - If you get any side effects , talk to your doctor. This includes any possible side effects not listed on this leaflet. See section 4. WHAT IS IN THIS LEAFLET: 1. What Vantas is and what it is used for 2. What you need to know before you use Vantas 3. How to use Vantas 4. Possible side effects 5. How to store Vantas 6. Contents of the pack and other information 1. WHAT VANTAS IS AND WHAT IT IS USED FOR • Vantas is a medicine delivery system which is surgically placed (or implanted) under the skin. • It is used for the treatment of advanced prostate cancer because it may help to relieve your prostate cancer symptoms. • The active substance is histrelin acetate. Each Vantas implant contains approximately 50 milligrams of histrelin acetate. After insertion under your skin, it releases 41 micrograms of histrelin (equivalent to 50 micrograms of histrelin acetate) per day into your body, over a period of 12 months. • Histrelin blocks your body from making and secreting hormones so that testosterone levels are reduced or cannot be detected in your blood. 2. WHAT YOU NEED TO KNOW BEFORE YOU USE VANTAS DO NOT USE VANTAS: • If you are ALLERGIC (hypersensitive) to the active substance, histrelin acetate, to other medicines called GnRH ( Pročitajte cijeli dokument
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Vantas 50 mg implant. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each implant contains approximately 50 mg histrelin acetate corresponding to 41 mg histrelin. For the full list of excipients, see section 6.1_._ 3 PHARMACEUTICAL FORM Implant. The implant is in the form of a small, thin flexible tube. The histrelin acetate core is placed in a non-biodegradable 34.5 mm x 3.15 mm cylindrically shaped hydrogel reservoir. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Palliative treatment of advanced prostate cancer. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION The recommended dose of Vantas is one implant for 12 months. An average of 50 µg histrelin acetate is delivered daily. The implant is inserted subcutaneously in the inner aspect of the upper arm. Response to Vantas therapy should be monitored by clinical parameters and by measuring prostate-specific antigen (PSA) serum levels. Clinical studies have shown that serum testosterone concentrations may increase during the first week of treatment (testosterone flare-up). Testosterone concentrations then decreased and reached castrate levels ( 50 ng/dL) by Week 4. Once attained, castrate level was maintained as long as Vantas therapy continued. If a patient's clinical response appears to be sub-optimal, then it would be advisable to confirm that patient’s serum testosterone concentration is at castrate level. The implant must be removed after 12 months of treatment. At the time the implant is removed a new implant may be inserted in order to continue the treatment. Please see insertion and removal procedures below. _PEDIATRIC POPULATION_ _Vantas is contraindicated for use in children under 18 years old as the safety and efficacy of Vantas have not been_ _est Pročitajte cijeli dokument